✦ LIBER ✦

A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109

✍ Scribed by Mina, Lida A.; Yu, Menggang; Johnson, Cynthia; Burkhardt, Cyndi; Miller, Kathy D.; Zon, Robin

Book ID: 121624813
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 112 KB
Volume: 31
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-013-9976-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sorafenib in combination with weekly top

Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group

✍ R. Ramasubbaiah; S.M. Perkins; J. Schilder; C. Whalen; C.S. Johnson; M. Callahan 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 268 KB

Phase I/II study of sorafenib with anast

Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer

✍ Claudine Isaacs; Pia Herbolsheimer; Minetta C. Liu; Mary Wilkinson; Yvonne Ottav 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 220 KB

A phase II study of bevacizumab in combi

A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer

✍ Lin, N. U.; Seah, D. S.; Gelman, R.; Desantis, S.; Mayer, E. L.; Isakoff, S.; Di 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 258 KB

A Phase II study of bevacizumab in combi

A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer

✍ Zhao, Meng; Pan, Xueliang; Layman, Rachel; Lustberg, Maryam B.; Mrozek, Ewa; Mac 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 403 KB

A phase II trial of combination chemothe

A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A southwest oncology group study

✍ Ronald M. Bukowski; Katherine G. Johnson; Robert F. Peterson; Ronald L. Stephens 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 504 KB

Phase II study of flutamide in patients

Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study

✍ Daniele J. Perrault; Diane M. Logan; David J. Stewart; Vivien H. C. Bramwell; Al 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 271 KB

The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of the oral antiandrogen flutamide in 33 patients with metastatic breast cancer. Eight patients had received no prior systemic therapy for their metastatic disease and 13 had only one site of metastasis.